Avadel Pharmaceuticals to Report Third Quarter 2017 Results
21 10월 2017 - 5:05AM
Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced it will
report its third quarter 2017 financial results on Wednesday,
November 8, 2017, before the market open. A conference call to
discuss these results has been scheduled for Wednesday, November 8,
2017 at 10:00 a.m. EDT. A question and answer period will follow
management's prepared remarks.
To access the conference call, investors are
invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393
(international). The conference ID number is 6289129. A live audio
webcast can be accessed by visiting the Investors section of the
Company’s website, www.avadel.com. A replay of the webcast will be
archived on Avadel’s website for 90 days following the event.
About Avadel Pharmaceuticals
plc: Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a
specialty pharmaceutical company that seeks to develop
differentiated pharmaceutical products that are safe, effective and
easy to take through formulation development, by utilizing its
proprietary drug delivery technology and in-licensing / acquiring
new products; ultimately, helping patients adhere to their
prescribed medical treatment and see better results. The Company is
headquartered in Dublin, Ireland with operations in St. Louis,
Missouri and Lyon, France. For more information, please visit
www.avadel.com.
Safe HarborThis press release
may include forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. The words “will,” “may,”
“believe,” “expect,” “anticipate,” “estimate,” “project” and
similar expressions, and the negatives thereof, identify
forward-looking statements, each of which speaks only as of the
date the statement is made. Although we believe that our
forward-looking statements are based on reasonable assumptions
within the bounds of our knowledge of our business and operations,
our business is subject to significant risks and as a result there
can be no assurance that actual results of our research,
development and commercialization activities and our results of
operations will not differ materially from the results contemplated
in such forward-looking statements. These risks include: (i) risks
relating to our license agreement with Serenity Pharmaceuticals,
LLC including that our internal analyses may overstate the market
opportunity in the United States and Canada for the drug
desmopressin acetate (the “Drug”) or we may not effectively exploit
such market opportunity, that significant safety or drug
interaction problems could arise with respect to the Drug, that we
may not successfully increase awareness of nocturia and the
potential benefits of the Drug, and that the need for management to
focus attention on the development and commercialization of the
Drug could cause our ongoing business operations to suffer; and
(ii) the other risks, uncertainties and contingencies described in
the Company's filings with the U.S. Securities and Exchange
Commission, including our annual report on Form 10-K for the year
ended December 31, 2016, in particular under the captions
“Forward-Looking Statements” and “Risk Factors,” including without
limitation: our dependence on a small number of products and
customers for the majority of our revenues; the possibility that
our Bloxiverz®,Vazculep® and Akovaz® products, which are not patent
protected, could face substantial competition resulting in a loss
of market share or forcing us to reduce the prices we charge for
those products; the possibility that we could fail to successfully
complete the research and development for pipeline products we are
evaluating for potential application to the FDA pursuant to our
"unapproved-to-approved" strategy, or that competitors could
complete the development of such products and apply for FDA
approval of such products before us; the possibility that our
products may not reach the commercial market or gain market
acceptance; our need to invest substantial sums in research and
development in order to remain competitive; our dependence on
certain single providers for development of several of our drug
delivery platforms and products; our dependence on a limited number
of suppliers to manufacture our products and to deliver certain raw
materials used in our products; the possibility that our
competitors may develop and market technologies or products that
are more effective or safer than ours, or obtain regulatory
approval and market such technologies or products before we do; the
challenges in protecting the intellectual property underlying our
drug delivery platforms and other products; and our dependence on
key personnel to execute our business plan. Except as may be
required by law, we disclaim any obligation to publicly update any
forward-looking statements to reflect events after the date of this
press release.
Contacts:Michael F.
KananChief Financial OfficerPhone: (636)
449-1844E-mail: mkanan@avadel.com
Lauren StivalSr.
Director, Investor Relations and Corporate
CommunicationsPhone: (636) 449-5866Email:
lstival@avadel.com
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024